CONCORD, Calif., Nov 12, 2010 (BUSINESS WIRE) -- Cerus Corporation (NASDAQ:CERS) announced today that Laurence Corash, M.D., senior vice president and chief medical officer, is scheduled to present a corporate update at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 2:10 pm EST. The conference will be held at The St. Regis Hotel in New York, New York.
A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://investor.cerus.com. A replay will be available for approximately two weeks following the completion of the event.
ABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
SOURCE: Cerus Corporation CONTACT: Cerus Corporation Lainie Corten, 925-288-6319 Director, Global Communications & Marketing Copyright Business Wire 2010 -0- KEYWORD: United States
California INDUSTRY KEYWORD: Health
Medical Devices SUBJECT CODE: Conference